1. SU11248 inhibits c-KIT and platelet-derived growth factor receptor-β in preclinical models of human small cell lung cancer;Abrams;Mol. Cancer Biol.,2003
2. Sunitinib: from rational design to clinical efficacy;Chow;J. Clin. Oncol. Res.,2007
3. Molecular basis for sunitinib efficacy and future clinical development;Faivre;Nat. Rev. Drug Discov.,2006
4. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period;Britten;Cancer Chemother. Pharmacol.,2008
5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin. Cancer Res.,2003